Gov- ernment policies in India, Europe, and the United States of America (USA) to procure and imple- ment biosimilars are not only about the safety and efficacy of the regimen, but also the potential cost-savings. [...] Awareness and education of biosimilars (rather than the originator) as a treatment option is an important step towards the development of policies that support safe and effective manage- ment and treatment, specific to the needs of patients and their medical conditions. [...] The meeting unpacked details related to physician and patient experiences and the level of awareness of biosimilars, along with the challenges and successes of implementing biosimilars policies globally, and the potential impact of mandatory non-medical switching to biosimilars policies on patients in Canada. [...] In Europe and the USA, biosimilars assume up to 60% of the total market of biologics merely after two years of launch, highlighting the success of biosimilars uptake. [...] Physicians should have the freedom to determine the most effective and safe treatment, based on scientific evidence and clinical experience, for the patient taking into consideration dura- tion of the disease and current treatment regime.
- Pages
- 8
- Published in
- Canada
